



ODG by MCG June 2025 Release

The next ODG release will be on Friday, June 27, 2025. This release contains updates to the following.

Treatment Guideline Updates

The following treatment guidelines are new:

- Amitriptyline for Mental Health
- Citalopram
- Escitalopram for Pain
- Fluoxetine for Pain
- Vilazodone for Pain

The following treatment guidelines have updates to their content, title, and ODG recommendation:

- Bupropion for Mental Health – conditionally recommended (CR) to recommended (R)
- Escitalopram for Mental Health – CR to R
- Fluoxetine for Mental Health – CR to R
- Incision and Drainage (I and D) – CR to R
- Lacosamide – CR to not recommended (NR)
- Paroxetine – CR to R
- Physician-Dispensed Drugs – Other (O) to NR
- Repackaged Drugs – O to definition (D)
- Sertraline – CR to R
- Vilazodone for Mental Health – NR to R
- Zonisamide – CR to NR

The following treatment guidelines have updates to their content:

- Cervical Facet Joint Sprain
- Hip Arthroplasty
- Knee Arthroplasty
- Physical/Occupational Therapy (PT/OT) for Pain



The following treatment guidelines have updates to their title and content:

- Allergy Skin Testing
- Airway Stent
- Interspinous Dynamic Spacer for Lumbar Degenerative Disc Disease
- Lung Positron Emission Tomography (PET) and PET-CT
- Polysomnography (PSG)
- Trazodone

The titles of several treatment guidelines have been updated.

The Summary of Changes for this content is available and located under the [“What’s New”](#) section on the Help & Training page.

The ODG application update will be available by the end of day on June 27, 2025.

If you have any questions or feedback, contact your ODG Account Manager or the ODG Helpdesk at odghelp@mcg.com.